SNDL Inc.
SNDL · XNASCIK 1766600fmd_0S0D07YDK38XPZQE5HTKW2ZB0GManufacturing · Medicinal Chemicals & Botanical ProductsTemplate: Standard
Coverage: Mar 01, 2017 to Dec 31, 2025, 8 periods
| Line item | FY2019 | FY2020 | FY2021 | FY2022 | FY2023 | FY2024 | FY2025 |
|---|---|---|---|---|---|---|---|
| Total revenues | 64 | 61 | 56 | 712 | 909 | 920 | 946 |
| Cost of revenue | 56 | – | – | – | 719 | 680 | 688 |
| Gross profit | 36 | (50) | (9) | 140 | 190 | 240 | 259 |
| Research and development | 2 | 0 | 2 | 2 | 0 | 0 | 0 |
| Selling, general and administrative | 47 | 38 | 43 | 149 | 215 | 199 | 197 |
| Operating income | (52) | (185) | (134) | (348) | (163) | (104) | (6) |
| Interest expense | 24 | 4 | 4 | 41 | 11 | 7 | 7 |
| Income before taxes | (146) | (206) | (235) | (380) | (172) | (106) | (16) |
| Net income from continuing operations | (143) | (206) | (227) | (372) | (172) | (96) | – |
| Net income | (271) | (233) | (227) | (335) | (173) | (95) | (16) |